From February 28: forbidden contrast for resonance with gadolinium

Italian medication agency: metal accumulates in small amounts in the brain
From February 28: forbidden contrast for resonance with gadolinium
27 February 00:55 2018 Print This Article

Starting from February 28, the use of common intravenous contrast agents based on gadolinium metal will be suspended in Italy. This was announced by the Italian Drug Agency (AIFA), based on the review conducted by the European Medicines Agency (EMA) which confirmed an accumulation of small amounts of gadolinium in brain tissues.
“There is currently no evidence that gadolinium deposits in the brain have caused damage to patients, however, since the long-term risks are not known, Ema recommended that linear contrast agents for intravenous use are suspended in the EU Healthcare professionals, according to AIFA, “will have to use gadolinium-based contrast agents only when it is not possible to obtain the necessary diagnostic information with non-intensified scans and use the lowest possible dose to provide sufficient intensification for the diagnosis “. The decision of the European Medicines Agency (EMA) to suspend the use of common gadolinium-based contrast agents “is for precautionary

Print this entry

view more articles

About Article Author